Physician profile
Rajiv Malik
NPI 1255314977
$20,111.51
in general payments reported to CMS, 2019-2025
89 companies · $3,384 in 2025
The $3,384 reported for 2025 was more than what 76% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,944 · 2020: $2,213 · 2021: $2,848 · 2022: $2,973 · 2023: $2,613 · 2024: $3,136 · 2025: $3,384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,100 · Education: $32.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,100.05 |
| Education | $32.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,488.11 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,342.16 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $1,298.42 | 2019-2025 | Darzalex, Tecvayli, Imbruvica |
| Astrazeneca Pharmaceuticals Lp | $1,227.67 | 2019-2025 | Calquence, Enhertu, Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $1,159.27 | 2019-2025 | Opdivo, Reblozyl, Opdualag |
| Pfizer INC. | $806.43 | 2019-2025 | |
| Genzyme Corporation | $784.85 | 2019-2025 | |
| Celgene Corporation | $652.05 | 2019-2025 | Reblozyl, Pomalyst, Pomalyst |
| Amgen INC. | $619.22 | 2019-2023 | Lumakras |
| Beigene USA, INC. | $602.58 | 2020-2025 | Brukinsa, Tevimbra |
| Glaxosmithkline, LLC. | $537.70 | 2020-2025 | Zejula, Ojjaara, Blenrep |
| Seagen INC. | $531.38 | 2019-2023 | Tukysa, Padcev |
| Astellas Pharma US INC | $510.28 | 2019-2025 | Vyloy, Xtandi, Padcev |
| Incyte Corporation | $491.34 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Genentech USA, INC. | $476.60 | 2019-2025 | Venclexta, Tecentriq, Polivy |
Show all 89 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajiv Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.